<DOC>
	<DOCNO>NCT00280176</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving bortezomib fluorouracil together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose bortezomib give together fluorouracil external-beam radiation therapy treat patient stage II , stage III , stage IV rectal cancer .</brief_summary>
	<brief_title>Bortezomib , Fluorouracil , External-Beam Radiation Therapy Treating Patients With Stage II , Stage III , Stage IV Rectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose bortezomib administer combination fluorouracil external beam radiotherapy preoperative palliative treatment patient stage II-IV rectal adenocarcinoma . - Determine dose-limiting toxicity regimen patient . Secondary - Determine dose-effect relationship bortezomib NF-kappa B activation induce chemoradiotherapy . - Determine downstream event induce NF-kappa B activation . - Determine downstream event related activation p53 response treatment chemoradiotherapy bortezomib . - Determine rate complete pathologic remission patient undergo surgical resection primary tumor . - Determine gene expression pattern tumor cDNA microarray analysis treatment regimen . OUTLINE : This multicenter , dose-escalation study bortezomib . Patients receive bortezomib IV day 1 , 4 , 8 , 11 , 22 , 25 , 29 , 32 fluorouracil IV continuously day 2-38 . Patients also undergo external beam radiotherapy 5 day week 5½ week . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients undergo tissue biopsy baseline day 1 2 . Samples collect evaluated tissue microarray analysis NF-kappa B pathway activation ; cDNA analysis , RNase protection assay , immunohistochemistry analysis downstream event induce NF-kappa B activation ; modify TdT-mediated dUTP nick-end label analysis apoptosis DNA fragmentation . NF-kappa B subunit quantify enzyme-linked immunosorbent assay . Serum sample collect baseline store future study . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsy confirm diagnosis adenocarcinoma rectum meet 1 follow clinical stag criterion : T3T4 , N0 , M0 ( stage II disease ) T4 disease define tumor fix examination involve adjacent pelvic structure , sidewall , bladder , uterus , prostate , small bowel ultrasound CT scan Any T , N12 , M0 ( stage III disease ) Any T , N , M1 ( stage IV disease ) Recurrent disease ( prior stage ) Candidate local palliative therapy curative resection metastatic disease Previously treat CNS disease allow provide stable &gt; 3 month PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month Adequate nutrition WBC ≥ 4,000/mm³ ANC &gt; 2,000/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 30 mL/min Bilirubin ≤ 1.5 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious medical psychiatric illness would limit study compliance limit survival &lt; 2 year No history refractory congestive heart failure cardiomyopathy No active coronary artery disease , myocardial infarction within past 3 month , cerebrovascular accident within past 3 month No peripheral neuropathy ≥ grade 2 No hypersensitivity bortezomib , boron , mannitol PRIOR CONCURRENT THERAPY : More 1 week since prior major surgery More 28 day since prior investigational agent Prior chemotherapy allow No prior pelvic radiotherapy ( treatment pelvic malignancy ) No concurrent herbal medication ( exclude vitamin mineral supplement ) No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>